AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28279371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraplaque hemorrhage
Number of subjects: 214
Study 28279371 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcification content in carotid plaques
Number of subjects: 214
Study 26047934 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 600
Study 26047934 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 600
Study 24006672 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspended moxibustion
Number of subjects: 56
Study 24006672 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (Control)
Number of subjects: 56
Study 21530213 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 0
Study 21530213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21530213 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-completers (both groups)
Number of subjects: 0
Study 18070787 — intervention group
Group type: EXPERIMENTAL
Intervention: AirWay Scope (AWS)
Number of subjects: 45
Study 18070787 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 45
Study 18070787 — intervention group
Group type: COMPARATOR
Intervention: McCoy laryngoscope
Number of subjects: 45
Study 18603947 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with combination of permanent and releasable scleral flap sutures (Group B)
Number of subjects: 34
Study 18603947 — intervention group
Group type: COMPARATOR
Intervention: Conventional trabeculectomy (Group A)
Number of subjects: 34
Study 18603947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 12585979 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-2 vaccine
Number of subjects: 10
Study 11098556 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF‐1
Number of subjects: 40
Study 11098556 — intervention group
Group type: COMPARATOR
Intervention: Heat-denatured growth factor (Control)
Number of subjects: 40
Study 8703450 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural plus general anesthesia with TMP-induced hypotension for 50 minutes
Number of subjects: 42
Study 8703450 — intervention group
Group type: COMPARATOR
Intervention: Epidural plus general anesthesia with SNP-induced hypotension
Number of subjects: 42
Study 8703450 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with SNP-induced hypotension
Number of subjects: 42
Study 8703450 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with TMP-induced hypotension for 20 minutes
Number of subjects: 42
Study 8703450 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural plus general anesthesia with TMP-induced hypotension
Number of subjects: 42
Study 1394809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillations of Adriamycin (ADM) at 20 mg/40 ml physiological saline for 2 years after TUR (Group A)
Number of subjects: 443
Study 1394809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillations of Adriamycin (ADM) at 20 mg/40 ml physiological saline for 2 weeks before TUR (Group B)
Number of subjects: 443
Study 1394809 — intervention group
Group type: COMPARATOR
Intervention: Control group undergoing TUR only (Group C)
Number of subjects: 443
Study 3886004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 36
Study 3886004 — intervention group
Group type: COMPARATOR
Intervention: Magnesium trisilicate
Number of subjects: 36
Study 29589416 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation (awake/cooperative sedation)
Number of subjects: 29
Study 29589416 — intervention group
Group type: COMPARATOR
Intervention: Caregivers (main caregivers of patients)
Number of subjects: 29
Study 29589416 — intervention group
Group type: COMPARATOR
Intervention: Caregivers (other ICU patients not enrolled in the study)
Number of subjects: 29
Study 29589416 — intervention group
Group type: COMPARATOR
Intervention: ICU staff (nurses, attending physicians, residents, medical students)
Number of subjects: 29
Study 28965100 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral resveratrol, 40 mg (two caplets) two times per day for 1 week, then 20 mg (one caplet) two times per day for a total of 6 months
Number of subjects: 164
Study 28965100 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 164
Study 28965100 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral resveratrol
Number of subjects: 164
Study 26296556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, multicomponent lifestyle interventions
Number of subjects: 0
Study 26296556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic design assessment using the PRECIS tool
Number of subjects: 0
Study 23948785 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (1000-3000 mg daily) plus α-lipoic acid (600-1800 mg daily)
Number of subjects: 40
Study 23948785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21615419 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (1000mg intramuscular long-acting testosterone undecanoate)
Number of subjects: 84
Study 21615419 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (33μg)
Number of subjects: 84
Study 21615419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline for men, matching placebo for women)
Number of subjects: 84
Study 18329882 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous coated prosthesis with solution-deposited HA
Number of subjects: 60
Study 18329882 — intervention group
Group type: COMPARATOR
Intervention: Prosthesis without HA
Number of subjects: 60
Study 16825680 — intervention group
Group type: COMPARATOR
Intervention: Low-LA diet (3% of energy from LA, 0.4% of energy from ALA, ALA-to-LA ratio = 1:7)
Number of subjects: 29
Study 16825680 — intervention group
Group type: COMPARATOR
Intervention: High-ALA diet (7% of energy from LA, 1.1% of energy from ALA, ALA-to-LA ratio = 1:7)
Number of subjects: 29
Study 16825680 — intervention group
Group type: EXPERIMENTAL
Intervention: Control diet (7% of energy from LA, 0.4% of energy from ALA, ALA-to-LA ratio = 1:19)
Number of subjects: 29
Study 15552357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues receiving strong inputs from other associates (e.g., car)
Number of subjects: 0
Study 15552357 — intervention group
Group type: COMPARATOR
Intervention: Attending to another task during or after study
Number of subjects: 0
Study 15552357 — intervention group
Group type: COMPARATOR
Intervention: Receiving implicit test instructions
Number of subjects: 0
Study 15552357 — intervention group
Group type: COMPARATOR
Intervention: Disruptions to retrieval of context features
Number of subjects: 0
Study 11172852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone plus GnRH analogue (leuprolide acetate and iron tablets)
Number of subjects: 66
Study 11172852 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus GnRH analogue (leuprolide acetate and iron tablets)
Number of subjects: 66
Study 11172852 — intervention group
Group type: COMPARATOR
Intervention: GnRH analogue (leuprolide acetate and iron tablets)
Number of subjects: 66
Study 9525541 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term anticoagulation
Number of subjects: 0
Study 9525541 — intervention group
Group type: COMPARATOR
Intervention: Observational data collection
Number of subjects: 0
Study 7837950 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HD) therapy
Number of subjects: 30
Study 7837950 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training combined with hypocaloric diet (AEX+HD)
Number of subjects: 30
Study 7837950 — intervention group
Group type: COMPARATOR
Intervention: Control group (HD vs AEX+HD)
Number of subjects: 30
Study 3287534 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (1-2 mg/kg)
Number of subjects: 7
Study 3287534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29668352 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (fluticasone furoate 100 μg, umeclidinium 62.5 μg, vilanterol 25 μg)
Number of subjects: 10355
Study 29668352 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate-vilanterol (100 μg and 25 μg)
Number of subjects: 10355
Study 29668352 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium-vilanterol (62.5 μg and 25 μg)
Number of subjects: 10355
Study 29668352 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 10355
Study 29668352 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium-vilanterol
Number of subjects: 10355
Study 27411768 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding empowerment program
Number of subjects: 55
Study 27411768 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 25054390 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA (Thoracic Epidural Analgesia)
Number of subjects: 30
Study 22585689 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin (KLH) - 16 adjuvant intravesical instillations after preimmunization
Number of subjects: 283
Study 22585689 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin (MM) - 11 adjuvant intravesical instillations
Number of subjects: 283
Study 22585689 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin (KLH)
Number of subjects: 283
Study 22585689 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin (MM)
Number of subjects: 283
Study 22585689 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-type hypersensitivity (DTH) response
Number of subjects: 283
Study 20079572 — intervention group
Group type: EXPERIMENTAL
Intervention: Procutase (Group B)
Number of subjects: 0
Study 20079572 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulphadiazine (SSD) (Group A)
Number of subjects: 0
Study 18410464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine (10 mg)
Number of subjects: 8
Study 18410464 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (30 mg)
Number of subjects: 8
Study 18410464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16822134 — intervention group
Group type: EXPERIMENTAL
Intervention: Attractor tap preceding attractee tap
Number of subjects: 0
Study 16822134 — intervention group
Group type: EXPERIMENTAL
Intervention: Attractor tap and attractee tap sequences
Number of subjects: 0
Study 16822134 — intervention group
Group type: COMPARATOR
Intervention: Gaze direction and concurrent auditory temporal information
Number of subjects: 0
Study 12798894 — intervention group
Group type: EXPERIMENTAL
Intervention: P1 medium supplemented with 0.5 mg/mL hyaluronic acid for 5‐10 min before intrauterine transfer
Number of subjects: 80
Study 12798894 — intervention group
Group type: COMPARATOR
Intervention: P1 medium containing 10% synthetic serum substitute (SSS)
Number of subjects: 80
Study 11004052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase 3.75 IU/mL
Number of subjects: 714
Study 11004052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase 7.5 IU/mL
Number of subjects: 714
Study 11004052 — intervention group
Group type: COMPARATOR
Intervention: No hyaluronidase
Number of subjects: 714
Study 8770965 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (10 mg i.v.)
Number of subjects: 9
Study 8770965 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 9
Study 8770965 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous angiotensin II infusion
Number of subjects: 9
Study 1628410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once daily
Number of subjects: 12
Study 1628410 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine slow release 40 mg twice daily
Number of subjects: 12
Study 6230629 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (Dichloromethylene diphosphonate)
Number of subjects: 10
Study 6230629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31606364 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid antagonists (MRAs) therapy maintained or increased during hospitalization
Number of subjects: 1589
Study 31606364 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) maintained or increased during hospitalization
Number of subjects: 1589
Study 31606364 — intervention group
Group type: EXPERIMENTAL
Intervention: Down-titration of MRAs during hospitalization
Number of subjects: 1589
Study 30307304 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (7 g)
Number of subjects: 20
Study 30307304 — intervention group
Group type: COMPARATOR
Intervention: Placebo (EX-PLA)
Number of subjects: 20
Study 30307304 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (7 g) alone (L-ARG)
Number of subjects: 20
Study 30307304 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-LARG (L-arginine + exercise)
Number of subjects: 20
Study 30307304 — intervention group
Group type: COMPARATOR
Intervention: EX-PLA (Placebo + exercise)
Number of subjects: 20
Study 26661687 — intervention group
Group type: EXPERIMENTAL
Intervention: HM (Home Monitoring)
Number of subjects: 1339
Study 25228130 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion during surgery (n = 33)
Number of subjects: 65
Study 22410137 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month daily rifampicin regimen (4R); n = 190
Number of subjects: 373
Study 22410137 — intervention group
Group type: COMPARATOR
Intervention: 6-month daily isoniazid regimen (6H); n = 183
Number of subjects: 373
Study 20858783 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete excavation
Number of subjects: 28
Study 20858783 — intervention group
Group type: COMPARATOR
Intervention: Complete excavation
Number of subjects: 28
Study 19111163 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with alum-formulated recombinant human GAD65
Number of subjects: 0
Study 19111163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15879822 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electromagnetic therapy (15 minutes at 10 Hz followed by 15 minutes at 50 Hz, twice weekly for 4 weeks)
Number of subjects: 21
Study 15879822 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 21
Study 12743130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based intraperitoneal treatment
Number of subjects: 0
Study 12743130 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cisplatin
Number of subjects: 0
Study 10562927 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 40
Study 10562927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10562927 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 subjects)
Number of subjects: 40
Study 10562927 — intervention group
Group type: EXPERIMENTAL
Intervention: Raynaud's group (40 patients)
Number of subjects: 40
Study 10562927 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI associated with provocation test
Number of subjects: 40
Study 10562927 — intervention group
Group type: EXPERIMENTAL
Intervention: Plethysmographic wave
Number of subjects: 40
Study 8867677 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly replacement schedule
Number of subjects: 12
Study 8867677 — intervention group
Group type: COMPARATOR
Intervention: Three monthly replacement schedule
Number of subjects: 12
Study 1987395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid drainage
Number of subjects: 98
Study 1987395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cerebrospinal fluid drainage)
Number of subjects: 98
Study 1987395 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hypotension
Number of subjects: 98
Study 3986081 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg doses of caffeine as an aqueous oral solution
Number of subjects: 12
Study 3986081 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg doses of caffeine as an intravenous infusion
Number of subjects: 12
Study 30851630 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg)
Number of subjects: 24
Study 30851630 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600 mg)
Number of subjects: 24
Study 29253351 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS)
Number of subjects: 16
Study 29253351 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 27272130 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (PA)
Number of subjects: 20266
Study 27272130 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational activity
Number of subjects: 20266
Study 27272130 — intervention group
Group type: EXPERIMENTAL
Intervention: Commuting physical activity
Number of subjects: 20266
Study 27272130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic factors
Number of subjects: 20266
Study 25149197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 105
Study 25149197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat/low-calorie diet
Number of subjects: 105
Study 25149197 — intervention group
Group type: EXPERIMENTAL
Intervention: FPQ diet preference
Number of subjects: 105
Study 21947604 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-enriched nutrients
Number of subjects: 25
Study 21947604 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 25
Study 20862933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with speech therapy
Number of subjects: 61
Study 20862933 — intervention group
Group type: COMPARATOR
Intervention: Speech therapy only (Control)
Number of subjects: 61
Study 22795211 — intervention group
Group type: EXPERIMENTAL
Intervention: d-serine 2 g/d
Number of subjects: 195
Study 22795211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 15593389 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased expression of aquaporin-4 (AQP4)
Number of subjects: 19
Study 15593389 — intervention group
Group type: EXPERIMENTAL
Intervention: AQP4 immunoreactivity around astrocytomas, ganglioglioma, and metastatic adenocarcinoma
Number of subjects: 19
Study 15593389 — intervention group
Group type: EXPERIMENTAL
Intervention: AQP4 immunoreactivity in centers of astrocytomas and ganglioglioma
Number of subjects: 19
Study 12704001 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF regimen (Cytoxan 600 mg/m(2), Adriamycin 60 mg/m(2), 5‐FU 600 mg/m(2))
Number of subjects: 117
Study 12704001 — intervention group
Group type: COMPARATOR
Intervention: TP regimen (paclitaxel 135 mg/m(2), cisplatin 60 mg/m(2))
Number of subjects: 117
Study 9585024 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) as a mass screening tool
Number of subjects: 0
Study 9585024 — intervention group
Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy (FS)
Number of subjects: 0
Study 9585024 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) and polypectomy
Number of subjects: 0
Study 8607102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent regional therapy with 20 mg rt-PA for 4 h each day
Number of subjects: 137
Study 8607102 — intervention group
Group type: COMPARATOR
Intervention: Systemic thrombolytic therapy with 20 mg rt-PA for 4 h each day
Number of subjects: 137
Study 8607102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (intermittent regional and systemic thrombolytic therapy)
Number of subjects: 137
Study 2776167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 88
Study 2776167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 1103743 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied griseofulvin in alcohol solution
Number of subjects: 0
Study 31840273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment (MBT)
Number of subjects: 46
Study 29884522 — intervention group
Group type: EXPERIMENTAL
Intervention: Square-stepping exercise (SSE) 2×/week for 24 weeks
Number of subjects: 25
Study 29884522 — intervention group
Group type: EXPERIMENTAL
Intervention: Square-stepping exercise (SSE)
Number of subjects: 25
Study 29884522 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 28216860 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training (1 hour, 3 sessions/week for 6 weeks)
Number of subjects: 36
Study 28216860 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie training (1 hour/day for 20 days)
Number of subjects: 36
Study 28216860 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study 26091917 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT‐i
Number of subjects: 148
Study 26091917 — intervention group
Group type: COMPARATOR
Intervention: Active control treatment
Number of subjects: 148
Study 26091917 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 148
Study 22108512 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 1052
Study 22108512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052
Study 21226754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered minimal psychological intervention
Number of subjects: 208
Study 21226754 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 208
Study 18641169 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology enhanced viewing condition (included additional Web‐support)
Number of subjects: 723
Study 18641169 — intervention group
Group type: COMPARATOR
Intervention: Standard viewing condition
Number of subjects: 723
Study 18641169 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (Technology enhanced and Standard)
Number of subjects: 723
Study 16635651 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine use (MAMP)
Number of subjects: 200
Study 16635651 — intervention group
Group type: COMPARATOR
Intervention: Control group (drug-free subjects)
Number of subjects: 200
Study 16635651 — intervention group
Group type: EXPERIMENTAL
Intervention: MAMP use
Number of subjects: 200
Study 14528134 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Buddy telehealth communication device
Number of subjects: 90